| Popis: |
Supplemental figure 7: (A) GR50 comparison of Mia PaCa2 (top) or Panc-1 (bottom) parental cells, and their respective "chronic" abemaciclib therapy cells once treated with abemaciclib. These "chronic" abemaciclib therapy cells were then liberated from abemaciclib exposure and cultured for 14 and 21 days and GR50 was re-tested after abemaciclib exposure. Mia PaCa 2 parental, Mia PaCa2 "chronic" abemaciclib therapy (denoted as MP CA, without abemaciclib 14 days or 21 days), Panc-1 parental and Panc-1 "chronic" abemaciclib therapy (denoted as P CA, without abemaciclib 14 days or 21 days) cells GR curves are plotted together on the same graph and shown in Supplemental figure 7A. MP CA= Mia PaCa2 "chronic" abemaciclib therapy cells, P CA= Panc-1 "chronic" abemaciclib therapy cells, w/o= without. (B) β-galactosidase staining quantification of Mia PaCa2 parental/ Mia PaCa2 "chronic" abemaciclib therapy cells (top), or Panc-1 parental/ Panc-1 "chronic" abemaciclib therapy cells (bottom), as collected 3, 5, or 7 days after plating with no additional drug treatment. (C) qPCR results of Mia PaCa2 (top) or Panc-1 (bottom) parental or "chronic" abemaciclib therapy cells evaluating for SASP markers. Samples were collected 3, 5, or 7 days after plating and normalized to the same day no treatment. MP CA= Mia PaCa2 "chronic" abemaciclib therapy cells, P CA= Panc-1 "chronic" abemaciclib therapy cells. |
